Table 3 Summary of pediatric melanomas (age < 20 years old) in the present study and comparison with other races using SEER database.
From: Clinical and histopathological characteristics of melanomas in Asians under age 40
Characteristics | Pediatric melanoma in present study‡ | Caucasians‡ 13 | Characteristics | Pediatric melanoma in present study‡ |
|---|---|---|---|---|
Age (years, median (range)) | 10.0 (4–19) | |||
Sex | 9 | 2197 | 212 | < 0.01* |
Female | 3 (33.3) | 1272 (57.9) | 134 (63.2) | |
Male | 6 (66.7) | 925 (42.1) | 78 (36.8) | |
Anatomical site | 9 | 2197 | 192 | < 0.001* |
Head and neck | 1 (11.1) | 482 (21.9) | 39 (18.4) | |
Upper extremities | 2 (22.2) | 393 (17.9) | 33 (15.6) | |
Trunk | 1 (11.1) | 789 (35.9) | 27 (22.2) | |
Lower extremities | 5 (55.6) | 486 (22.1) | 85 (40.1) | |
Unavailable | 0 (0.0) | 47 (2.1) | 8 (3.8) | |
Morphology | 9 | |||
Macular | 5 (55.5) | |||
Nodular | 4 (44.4) | |||
Ulceration clinically | 9 | |||
Yes | 0 (0.0) | |||
No | 9 (100.0) | |||
Amelanosis | 9 | |||
Yes | 4 (44.4) | |||
No | 5 (55.5) | |||
Breslow thickness(mm, mean (range)) | 5.5 (2.5–14) | |||
Ulceration histologically | 8 | 1923 | 145 | 0.99 |
Yes | 0 (0.0) | 50 (2.4) | 3 (1.8) | |
No | 8 (100.0) | 1873 (90.4) | 142 (85.5) | |
Mitosis (≥ 1/mm2) | 2 (25.0) | 230 (10.6) | 22 (12.0) | |
Lymphovascular invasion | 4 | |||
Yes | 0 (0.0) | |||
No | 4 (100.0) | |||
Perineural invasion | 4 | |||
Yes | 0 (0.0) | |||
No | 4 (100.0) | |||
Histologic types | 9 | 2199 | 197 | < 0.001* |
Superficial spreading | 0 (0.0) | 706 (32.1) | 34 (17.3) | |
Lentigo maligna | 1 (11.1) | 2 (0.1) | 0 (0.0) | |
Acral lentiginous | 3(33.3) | 15 (0.7) | 1 (0.5) | |
Nodular | 1 (11.1) | 140 (6.4) | 20 (10.2) | |
Spitzoid | 4 (44.4) | 495 (22.2) | 72 (36.5) | |
Others | 0 (0.0) | 155 (7.0) | 29 (14.7) | |
Unavailable | 0 (0.0) | 686 (31.2) | 41 (20.9) | |
Stage T | 9 | |||
pTis | 3(33.3) | |||
pT1 | 0 (0.0) | |||
pT2 | 0 (0.0) | |||
pT3 | 4 (44.4) | |||
pT4 | 2 (22.2) | |||
Lymph node involvement at diagnosis | 9 | 971 | 105 | 0.047* |
Yes | 1 (11.1) | 301 (31.0) | 43 (41.0) | |
No | 8 (88.9) | 670 (69.0) | 62 (59.0) | |
Distant metastasis at diagnosis | 9 | |||
Yes | 0 (0.0) | |||
No | 9 (100.0) | |||
Stage | 9 | |||
In situ | 3 (33.3) | |||
I | 0 (0.0) | |||
II | 5 (55.5) | |||
III | 1 (11.1) | |||
IV | 0 (0.0) | |||
Survival | 9 | |||
Dead | 1 (11.1) | |||
Alive | 8 (88.9) | |||
Overall survival (months, mean (range)) | 66.2 (6–127) | |||
Progression | 9 | |||
Yes | 0 (0.0) | |||
No | 9 (100.0) |
